Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

Phase 1
Completed
Conditions
Acute Undifferentiated Leukemia
B-cell Adult Acute Lymphoblastic Leukemia
B-cell Childhood Acute Lymphoblastic Leukemia
L1 Adult Acute Lymphoblastic Leukemia
L1 Childhood Acute Lymphoblastic Leukemia
L2 Adult Acute Lymphoblastic Leukemia
L2 Childhood Acute Lymphoblastic Leukemia
Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia
Interventions
Drug: allopurinol
Drug: cyclophosphamide
Drug: daunorubicin hydrochloride
Drug: vincristine sulfate
Drug: dexamethasone
Drug: asparaginase
Biological: filgrastim
Drug: imatinib mesylate
Drug: methotrexate
Drug: cytarabine
Drug: trimethoprim-sulfamethoxazole
Drug: mercaptopurine
Drug: leucovorin calcium
Biological: alemtuzumab
Drug: acyclovir
Other: laboratory biomarker analysis
Other: pharmacological study
First Posted Date
2003-06-06
Last Posted Date
2022-05-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
302
Registration Number
NCT00061945
Locations
🇺🇸

Cancer and Leukemia Group B, Chicago, Illinois, United States

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

First Posted Date
2003-05-21
Last Posted Date
2013-08-21
Lead Sponsor
Children's Oncology Group
Target Recruit Count
83
Registration Number
NCT00005977
Locations
🇺🇸

Emory University Hospital - Atlanta, Atlanta, Georgia, United States

🇺🇸

St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States

🇺🇸

Texas Oncology P.A., Dallas, Texas, United States

and more 116 locations

A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide

First Posted Date
2003-05-07
Last Posted Date
2012-09-25
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
41
Registration Number
NCT00005793
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia

Phase 3
Completed
Conditions
Leukemia
Myelodysplastic Syndromes
First Posted Date
2003-04-30
Last Posted Date
2013-12-04
Lead Sponsor
Medical Research Council
Target Recruit Count
2000
Registration Number
NCT00003436
Locations
🇬🇧

Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom

Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

First Posted Date
2003-04-25
Last Posted Date
2018-11-14
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
19
Registration Number
NCT00003311
Locations
🇺🇸

University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Phase 3
Completed
Conditions
Leukemia
First Posted Date
2003-04-16
Last Posted Date
2012-04-13
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
61
Registration Number
NCT00002945
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia

Phase 3
Conditions
Leukemia
First Posted Date
2003-04-11
Last Posted Date
2013-09-20
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
750
Registration Number
NCT00002701
Locations
🇧🇪

Universitair Ziekenhuis Antwerpen, Edegem, Belgium

🇮🇹

Federico II University Medical School, Naples (Napoli), Italy

🇮🇹

Ospedale S. Gennora USL 42, Naples (Napoli), Italy

and more 68 locations

Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia

Phase 3
Conditions
Leukemia
Neutropenia
First Posted Date
2003-04-10
Last Posted Date
2013-12-19
Lead Sponsor
Medical Research Council
Target Recruit Count
2000
Registration Number
NCT00002658
Locations
🇬🇧

University of Wales College of Medicine, Cardiff, Wales, United Kingdom

Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

First Posted Date
2003-04-09
Last Posted Date
2013-10-08
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
82
Registration Number
NCT00058461
Locations
🇺🇸

Children's Oncology Group, Arcadia, California, United States

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

First Posted Date
2003-04-09
Last Posted Date
2012-06-01
Lead Sponsor
Northwestern University
Target Recruit Count
44
Registration Number
NCT00058292
Locations
🇺🇸

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

🇺🇸

Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States

🇺🇸

Mayo Clinic Cancer Center, Rochester, Minnesota, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy